CW Advisors LLC Increases Stake in AstraZeneca PLC $AZN

CW Advisors LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 106.9% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 33,750 shares of the company’s stock after purchasing an additional 17,438 shares during the quarter. CW Advisors LLC’s holdings in AstraZeneca were worth $2,356,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AZN. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of AstraZeneca during the second quarter valued at approximately $117,000. Pinkerton Wealth LLC lifted its position in AstraZeneca by 2.9% in the 2nd quarter. Pinkerton Wealth LLC now owns 65,845 shares of the company’s stock valued at $4,601,000 after acquiring an additional 1,880 shares in the last quarter. Beacon Pointe Advisors LLC boosted its stake in AstraZeneca by 4.2% during the 2nd quarter. Beacon Pointe Advisors LLC now owns 21,360 shares of the company’s stock valued at $1,493,000 after purchasing an additional 862 shares during the last quarter. Blueshift Asset Management LLC bought a new stake in shares of AstraZeneca in the 2nd quarter worth $258,000. Finally, Portfolio Design Labs LLC raised its stake in shares of AstraZeneca by 24.4% in the second quarter. Portfolio Design Labs LLC now owns 3,431 shares of the company’s stock worth $240,000 after purchasing an additional 674 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AZN opened at $90.18 on Friday. The company’s 50 day moving average is $86.06 and its 200 day moving average is $78.45. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The company has a market cap of $279.69 billion, a price-to-earnings ratio of 29.96, a PEG ratio of 1.67 and a beta of 0.32. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $94.01.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05. The business had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The company’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period last year, the firm earned $2.08 earnings per share. On average, equities research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on AZN. Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Wednesday. Jefferies Financial Group began coverage on shares of AstraZeneca in a report on Monday, October 27th. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of $91.67.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.